Review
Psychiatry
Shu-Wen Deng, Qian Xu, Wen-Long Jiang, Bo Hong, Bo-Hui Li, Da-Wei Sun, Hai-Bo Yang
Summary: This study compared the efficacy and safety of blonanserin and risperidone in the treatment of schizophrenia. The results showed no difference in efficacy between the two drugs, but blonanserin had a lower incidence of serum prolactin increases and weight gain, and a higher incidence of extrapyramidal symptoms compared to risperidone.
Article
Clinical Neurology
Shimeng Dong, Johannes Schneider-Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto Samara, Stefan Leucht
Summary: In this network meta-analysis, the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia were examined. The results showed that clozapine and olanzapine were more effective in relieving symptoms compared to other drugs. Clozapine remains the gold standard for patients with treatment-resistant schizophrenia, while olanzapine can be considered as an alternative option.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2023)
Article
Pediatrics
Takuya Saito, Saori Sugimoto, Reiko Sakaguchi, Hiroshi Nakamura, Jun Ishigooka
Summary: This study evaluated the short-term efficacy and safety of blonanserin in adolescents with schizophrenia. The results showed that blonanserin at a dosage of 16 mg/day was more effective in reducing symptoms compared to the placebo group. The incidence of adverse events in the blonanserin groups was slightly higher, but they were generally mild and consistent with those observed in adults.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yoshifumi Inoue, Kimiko Tsuchimori, Hiroshi Nakamura
Summary: Blonanserin, a novel second-generation antipsychotic, has shown beneficial effects on patients with schizophrenia in real clinical practice. Despite common adverse reactions, its effectiveness is maintained even after long-term use.
JOURNAL OF PHARMACOLOGICAL SCIENCES
(2021)
Article
Psychiatry
Qijing Bo, Xijin Wang, Xuejun Liu, Hong Sang, Zhiyuan Xun, Ruiling Zhang, Xiaodong Yang, Huaili Deng, Keqing Li, Jindong Chen, Meijuan Sun, Guijun Zhao, Xianglai Liu, Duanfang Cai, Guilai Zhan, Juhong Li, Haiyun Li, Gang Wang
Summary: This study evaluated the effectiveness and safety of oral blonanserin in Chinese young and middle-aged female patients with schizophrenia through post-marketing surveillance. The results showed that blonanserin significantly improved symptoms and had a low tendency for metabolic side effects. This suggests that blonanserin may be a reasonable choice for the treatment of schizophrenia in this patient population.
Article
Clinical Neurology
Kazutaka Ohi, Kentaro Takai, Ayumi Kuramitsu, Shunsuke Sugiyama, Toshiki Shioiri
Summary: This study found that transdermal patches of blonanserin are a more effective route of administration to reduce EPS compared to oral tablets/powder.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2022)
Article
Neurosciences
Takeshi Sakayori, Amane Tateno, Ryosuke Arakawa, Woo-chan Kim, Yoshiro Okubo
Summary: The study showed that blonanserin occupied both D-2 and D-3 receptors in patients with schizophrenia.
PSYCHOPHARMACOLOGY
(2021)
Article
Pediatrics
Takuya Saito, Yohei Hyodo, Reiko Sakaguchi, Hiroshi Nakamura, Jun Ishigooka
Summary: This study evaluated the long-term efficacy and safety of oral blonanserin in adolescents with schizophrenia. Results showed that blonanserin treatment improved or stabilized psychiatric symptoms in patients with adolescent schizophrenia, with good safety profile.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Ying Lu, Yu Tian, Yu Gan, Yixiao Fu, Qibin Chen, Lei Zou, Bangshu Zhao, Yu Yan, Shudong Liu, Xiaolu Chen, Xiao Li
Summary: This study evaluates the efficacy and tolerability of electroconvulsive therapy (ECT) in psychiatric patients with arachnoid cysts. The results show that ECT is an effective and tolerable therapy for these patients.
Review
Clinical Neurology
Tien-Wei Hsu, Che-Sheng Chu, Pao-Yuan Ching, Guan-Wei Chen, Chih-Chuan Pan
Summary: This study conducted a systematic review and meta-analysis to evaluate the antidepressant effects of memantine in patients with major mental diseases. The results showed that memantine effectively alleviates depressive symptoms in patients with mood disorders with a small effect size, but it does not have a significant effect in patients with schizophrenia.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Chemistry, Analytical
Shan-qing Huang, Xiao-lin Li, Zhan-zhang Wang, Hao-yang Lu, Tao Xiao, Xiao-jia Ni, Shu-jing Liu, Ming Zhang, De-wei Shang, Yu-guan Wen
Summary: A high-performance liquid chromatographic method coupled with triple quadrupole mass spectrometry has been developed and validated for the analysis of blonanserin and its active metabolite, N-desethyl blonanserin, in rat plasma. The method showed sufficient accuracy and precision and was successfully applied in a pharmacokinetic study in rats.
JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY
(2022)
Review
Clinical Neurology
Tahir Hakami
Summary: Drug-resistant epilepsy affects 25-30% of patients, with 30-40% of individuals failing treatment with first-generation antiseizure drugs due to intolerable adverse effects. In recent years, 20 newer-generation ASDs have been introduced, expanding treatment options for epilepsy. Research has focused on defining the optimal ASD for different seizure types.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Psychiatry
Haishan Wu, Xijin Wang, Xuejun Liu, Hong Sang, Qijing Bo, Xiaodong Yang, Zhiyuan Xun, Keqing Li, Ruiling Zhang, Meijuan Sun, Duanfang Cai, Huaili Deng, Guijun Zhao, Juhong Li, Xianglai Liu, Guilai Zhan, Jindong Chen
Summary: This study evaluated the safety and effectiveness of blonanserin in Chinese patients with schizophrenia. The results demonstrated the drug to be safe and effective.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Multidisciplinary Sciences
Jiaojiao Pang, Feng Xu, Gianmarco Aondio, Yu Li, Alberto Fumagalli, Ming Lu, Giuseppe Valmadre, Jie Wei, Yuan Bian, Margherita Canesi, Giovanni Damiani, Yuan Zhang, Dexin Yu, Jun Chen, Xiang Ji, Wenhai Sui, Bailu Wang, Shuo Wu, Attila Kovacs, Miriam Revera, Hao Wang, Xu Jing, Ying Zhang, Yuguo Chen, Yihai Cao
Summary: In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO(2) ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.
NATURE COMMUNICATIONS
(2021)
Article
Clinical Neurology
Hironori Nishibe, Amane Tateno, Takeshi Sakayori, Masahiro Yamamoto, WooChan Kim, Hiroyoshi Kakuyama, Yoshiro Okubo
Summary: Transdermal antipsychotic patch formulations, specifically blonanserin patches at doses of 40 mg/d and 80 mg/d, exhibit lower diurnal variability in occupancy compared to blonanserin tablets at doses of 8 mg/d and 16 mg/d, indicating that patches may be a suitable alternative for patients with schizophrenia. The study suggests that blonanserin patches could potentially offer a new treatment option for these patients.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2021)
Review
Clinical Neurology
Yong-Ku Kim, Meysam Amidfar, Eunsoo Won
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Review
Clinical Neurology
Kyu-Man Han, Domenico De Berardis, Michele Fornaro, Yong-Ku Kim
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Review
Clinical Neurology
Yong-Ku Kim, Byung-Joo Ham, Kyu-Man Han
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Review
Psychiatry
Seon-Cheol Park, Yong-Ku Kim
PSYCHIATRY INVESTIGATION
(2019)
Review
Pharmacology & Pharmacy
Carmine Tomasetti, Chiara Montemitro, Annastasia L. C. Fiengo, Cristina Santone, Laura Orsolini, Alessandro Valchera, Alessandro Carano, Maurizio Pompili, Gianluca Serafini, Giampaolo Perna, Federica Vellante, Giovanni Martinotti, Massimo D. Giannantonio, Yong-Ku Kim, Marco D. Nicola, Antonello Bellomo, Antonio Ventriglio, Michele Fornaro, Domenico D. Berardis
CURRENT PHARMACEUTICAL DESIGN
(2019)
Article
Clinical Neurology
Kyu-Man Han, Hee-Jung Jee, Hyonggin An, Cheolmin Shin, Ho-Kyoung Yoon, Young-Hoon Ko, Byung-Joo Ham, Yong-Ku Kim, Changsu Han
JOURNAL OF AFFECTIVE DISORDERS
(2019)
Review
Clinical Neurology
Meysam Amidfar, Marie Woelfer, Gislaine Z. Reus, Joao Quevedo, Martin Walter, Yong-Ku Kim
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Review
Psychiatry
Seon-Cheol Park, Yong-Ku Kim
PSYCHIATRY INVESTIGATION
(2019)
Editorial Material
Psychiatry
Seon-Cheol Park, Yong-Ku Kim
PSYCHIATRY INVESTIGATION
(2019)
Editorial Material
Neurosciences
Youn Jung Lee, Yong-Ku Kim
CURRENT NEUROPHARMACOLOGY
(2020)
Article
Pharmacology & Pharmacy
Cheolmin Shin, Yong-Ku Kim
CURRENT OPINION IN PHARMACOLOGY
(2019)
Review
Biochemistry & Molecular Biology
Eunsoo Won, Yong-Ku Kim
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Review
Biochemistry & Molecular Biology
Junhyung Kim, Yong-Ku Kim
Summary: Alzheimer's disease is the most common type of dementia, with depression being a risk factor for its development. While depression patients often recover without residual symptoms, late-life depression patients may show residual cognitive impairment. Understanding how risk factors impact the course of Alzheimer's disease is crucial for its management.
Review
Biochemistry & Molecular Biology
Lorenza Lucidi, Mauro Pettorruso, Federica Vellante, Francesco Di Carlo, Franca Ceci, Maria Chiara Santovito, Ilenia Di Muzio, Michele Fornaro, Antonio Ventriglio, Carmine Tomasetti, Alessandro Valchera, Alessandro Gentile, Yong-Ku Kim, Giovanni Martinotti, Silvia Fraticelli, Massimo Di Giannantonio, Domenico De Berardis
Summary: The gut microbiota plays a crucial role in maintaining homeostasis, growth, and digestive processes. It also influences the intercommunication system between the gut and the brain, potentially impacting the pathogenesis and clinical management of Bipolar Disorder. Current literature suggests a relationship between compositional alterations in the gut microbiota and BD, with potential benefits in treating BD symptoms through modifications in the microbiota composition. Further research is needed to explore the potential of correcting gut microbiota alterations as a novel strategy in BD management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Eunsoo Won, Kyoung-Sae Na, Yong-Ku Kim
Summary: Inflammatory conditions and disruptions in circadian rhythms, including alterations in the melatonin system, have been suggested as mechanisms underlying major depressive disorder. Melatonin, with its immunological and non-immunological actions, can suppress inflammation and influence neuroinflammation and neurotoxicity, leading to alterations in brain regions implicated in depression. Further research on the associations between melatonin, immune markers, and brain structure and function may help identify potential biomarkers for MDD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)